Engraftment and outcome after autologous stem cell transplantation in plerixafor‐mobilized non‐<scp>H</scp>odgkin's lymphoma patients

Varmavuo, Ville; Rimpiläinen, Johanna; Kuitunen, Hanne; Nihtinen, Anne; Vasala, Kaija; Mikkola, Maija; Kutila, Anu; Lehtonen, Päivi; Kuittinen, Taru; Mäntymaa, Pentti; Nousiainen, Tapio; Kuittinen, Outi; Jantunen, Esa

doi:10.1111/trf.12434

Cited by 27 publications

(27 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Holtan et al 32 showed better PFS in a small series of patients mobilized with G-CSF and plerixafor when compared with G-CSF alone; this result was not confirmed in a recent retrospective study 33 conducted on 89 NHL patients, in which PFS at 1 year after auto-SCT was comparable (79% and 86% in the plerixafor group and the control group, respectively).…”

Section: Cd34 + Stem Cell Dose For Autologous Transplant In the Plerimentioning

confidence: 76%

See 1 more Smart Citation

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Saraceni

Shem‐Tov

Olivieri

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Although stem cell mobilization has been performed for more than 20 years, little is known about the effects of mobilizing agents on apheresis composition and the impact of graft cell subsets on patients' outcome. With the increasing use of plerixafor and the inclusion of poor mobilizers in autologous transplant procedures, new parameters other than CD34 + stem cell dose are emerging; plerixafor seems to mobilize more primitive CD34 + /CD38 − stem cells compared with G-CSF, but their correlation with stable hematopoietic engraftment is still obscure. Immune recovery is as crucial as hematopoietic reconstitution, and higher T and natural killer cells infused within the graft have been correlated with better outcome in autologous transplant; recent studies showed increased mobilization of immune effectors with plerixafor compared with G-CSF, but further data are needed to clarify the clinical impact of these findings. In the allogeneic setting, much evidence suggests that mobilized T-cell alloreactivity is tempered by G-CSF, probably with the mediation of dendritic cells, even though no clear correlation with GVL and GVHD has been found. Plerixafor is not approved in healthy donors yet; early data suggest it might mobilize a GVHD protective balance of immune effectors, but further studies are needed to define its role in allogeneic transplant.

show abstract

Section: Cd34 + Stem Cell Dose For Autologous Transplant In the Plerimentioning

confidence: 76%

“…• A-ALC40.5 × 10 9 /kg predicts better OS and PFS A-ALC independent prognostic factor for OS and DFS 22 Porrata et al 21 • a A-ALC40.5 × 10 9 /kg predicts better OS and PFS A-ALC independent prognostic factor for OS and PFS 21 Holtan et al, 32 Varmavuo et al 33 and Gaugler et al 27 •…”

Section: Cd34 + Stem Cell Dose For Autologous Transplant In the Plerimentioning

confidence: 99%

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Saraceni

Shem‐Tov

Olivieri

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Most of the other authors did not provide information about gating strategies but also reported higher proportions of CD38-/CD341 cells after plerixafor compared to G-CSF alone. [8][9][10]12,13 In addition, Taubert and coworkers 14 found increased proportions of CD38-cells after plerixafor mobilization and reported higher CD133 mRNA levels in CD341/ALDH bright cells. Based on recent studies describing a revision of the hematopoietic tree, 15,16 we established a multicolor single-platform analysis to enumerate CD34 subtypes of stem cell grafts.…”

Section: Discussionmentioning

confidence: 98%

“…Subsequent reports showed similar results. However, none of these groups described their gating strategies or showed figures depicting how “CD38 dim ” “CD38 low ” or “CD38 negative ” cells had been defined . Various groups have developed the model of a hematopoietic tree, describing the differentiation from the earliest CD34+ MPPs to lineage‐committed CD34+ precursors giving rise to defined blood cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes

Worel¹,

Frank

Frech

et al. 2017

Transfusion

View full text Add to dashboard Cite

In contrast to the findings of other authors, our study shows a clear shift toward more committed CD34+ subsets after plerixafor in poor mobilizers and elucidates the importance of informative surface markers like CD45RA and CD133 in addition to CD38 to discriminate earlier from more committed CD34+ cells. Further studies are needed to analyze whether these findings have an impact on clinical outcome.

show abstract

Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor

Yuan

Palmer

Tsai

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

Plerixafor has been used to improve peripheral blood stem cell (PBSC) mobilization in multiple myeloma, non-Hodgkin lymphoma, and very recently in Hodgkin lymphoma (HL) patients. Because prior studies have suggested that mobilization with plerixafor affects the composition of mobilized cells, there are concerns that this may in turn adversely impact the immune reconstitution and longer term outcomes of transplanted patients. However, data on the engraftment characteristics and long-term post-transplant outcomes in patients transplanted with plerixafor-mobilized PBSCs are lacking. This retrospective study examined the post-transplant outcomes of 105 consecutive adult HL patients, and compared the post-transplant outcomes of 21 patients who received plerixafor in addition to G-CSF ± chemotherapy because of poor mobilization with those of 84 patients who mobilized well without plerixafor. Despite collecting significantly lower CD34+ cell doses (median of 3.41 vs. 6.05 × 10 /kg, p < 0.0001) than control patients and requiring more collection days, plerixafor-mobilized patients showed comparable early engraftment characteristics, except for slightly delayed neutrophil engraftment (median: 11 vs.10 days, p = 0.002) and lower median neutrophil counts (2.1 vs. 2.6 × 10 /L, p = 0.04) at one month after transplant. No significant differences were observed in longer term post-transplant outcomes, including cell counts at 3, 6, and 12 months, RBC and platelet transfusion support during the first 120 days, relapse incidence, overall and progression-free survival rates up to two years post transplant. The use of plerixafor not only enabled poorly mobilizing HL patients to collect enough PBSCs to proceed to ASCT, but also to have similar post-transplant outcomes compared to patients who mobilized well with conventional regimens. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Engraftment and outcome after autologous stem cell transplantation in plerixafor‐mobilized non‐Hodgkin's lymphoma patients

Abstract: Long-term engraftment and outcome after ASCT seem to be comparable in NHL patients receiving plerixafor compared to chemomobilized patients. These observations support the use of plerixafor in patients who mobilize poorly.

Cited by 27 publications

References 46 publications

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes

Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor

Contact Info

Product

Resources

About